Naldemedine + Placebo

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Opioid Induced Bowel Dysfunction

Conditions

Opioid Induced Bowel Dysfunction

Trial Timeline

May 19, 2010 → Mar 22, 2011

NCT ID

NCT01122030

About Naldemedine + Placebo

Naldemedine + Placebo is a phase 2 stage product being developed by Shionogi for Opioid Induced Bowel Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT01122030. Target conditions include Opioid Induced Bowel Dysfunction.

What happened to similar drugs?

8 of 20 similar drugs in Opioid Induced Bowel Dysfunction were approved

Approved (8) Terminated (6) Active (7)

✅Naldemedine + PlaceboShionogiApproved

✅Polyethylene Glycol 3350 + MovantikAstraZenecaApproved

✅Naltrexone for extended-release injectable suspension + Oral naltrexoneAlkermesApproved

✅NaltrexoneAlkermesApproved

✅VIVITROL 380mgAlkermesApproved

✅methylnaltrexone + placeboBausch HealthApproved

✅Methylnaltrexone bromideBausch HealthApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07038551	Approved	Recruiting	Jun 6, 2025	Sep 30, 2027	Opioid-Induced Constipation (OIC)
NCT04355169	Phase 2	Terminated	Nov 6, 2020	Jan 4, 2021	Postoperative Gastrointestinal Dysfunction
NCT01993940	Phase 3	Completed	Nov 4, 2013	Jun 9, 2015	Opioid-induced Constipation
NCT01965652	Phase 3	Completed	Sep 24, 2013	Jan 12, 2016	Opioid-induced Constipation
NCT01965158	Phase 3	Completed	Aug 29, 2013	Jan 22, 2015	Opioid-induced Constipation
NCT01122030	Phase 2	Completed	May 19, 2010	Mar 22, 2011	Opioid Induced Bowel Dysfunction

Competing Products

20 competing products in Opioid Induced Bowel Dysfunction

See all competitors

Product	Company	Stage	Hype Score
SUBLOCADE	Indivior PLC	Phase 3	29
SUBLOCADE	Indivior PLC	Phase 3	29
ASP8082 + morphine + Placebo	Astellas Pharma	Phase 1	29
ASP8062 + Placebo ASP8062 + buprenorphine/naloxone	Astellas Pharma	Phase 1	29
ASP8062 + Placebo ASP8062 + buprenorphine/naloxone	Astellas Pharma	Phase 2	27
Naldemedine + Placebo	Shionogi	Phase 3	40
Naldemedine + Placebo	Shionogi	Approved	50
Naldemedine	Shionogi	Phase 1/2	39
Naldemedine + Placebo	Shionogi	Phase 3	40
Placebo + Naldemedine	Shionogi	Phase 2	35
Naldemedine + Placebo	Shionogi	Phase 3	40
Naloxegol	Kyowa Kirin	Pre-clinical	26
naloxegol + non-PAMORA laxative	Kyowa Kirin	Pre-clinical	18
Naloxegol	Kyowa Kirin	Pre-clinical	26
Naloxegol	Kyowa Kirin	Pre-clinical	26
Brenipatide + Placebo + Buprenorphine	Eli Lilly	Phase 2	42
NKTR-118 + NKTR-118 + Placebo	AstraZeneca	Phase 3	32
Naloxegol + Naloxegol	AstraZeneca	Phase 1	29
NKTR-118 + Usual care	AstraZeneca	Phase 3	40
Polyethylene Glycol 3350 + Movantik	AstraZeneca	Approved	43